Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Applied Therapeutics has a business model that defies the conventional wisdom about start-up success: reviving science abandoned by big pharma; financing from a narrow group of investors, dependent on the goodwill of a single academic institution; all in pursuit of a small molecule solution to one of the biggest, diversely complex and cost-defying challenges in chronic disease – the complications of diabetes.
Infographic: In Vivo explores trends in personalized medicine, looking at the 25 new molecular entities approved in the US last year with an individualized aspect.
Genomic medicine is coming of age. For Illumina chief scientific officer David Bentley, that not only means improved technology, accuracy and coverage of gene sequencing and a broadening into cancer, but also a better understanding among the wider population of disease and precisely the benefits that gene sequencing can bring to patients – actual and pre-symptomatic.
Once the stuff of (largely implausible) science fiction, gene therapy is now a clinical reality and one that is taking an increasing share of the pharma R&D limelight. In Vivo takes a look at how these therapies work, how the field has emerged and where it is likely to go next.
A bill that would promote genetic testing for infants and children, introduced by California Rep. Eric Swallwell, is gaining support in the US House of Representatives.
Academic research has once again demonstrated itself to the oxygen of inspiration for industry drug innovation, including a blockbuster-in-waiting
There are "tremendous concerns" about potential abuse of biomarkers to diagnose pain, Stanford University researcher tells FDA Science Forum.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.
In October, health IT startup LifePod will debut its proactive voice-assistant device for caregivers to help improve care of the elderly. The device differs from other voice services by including a proactive dialogue to remind the aging person of appointments, events and medications, and gives caregivers real-time feedback on how well patients are doing.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.